{"id":35962,"date":"2026-08-12T17:39:00","date_gmt":"2026-08-12T12:09:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35962"},"modified":"2026-08-12T15:59:54","modified_gmt":"2026-08-12T10:29:54","slug":"artificial-pancreas-device-systems-in-diabetes-management","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management","title":{"rendered":"Artificial Pancreas Device Systems: Engineering a New Era in Diabetes Management"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a7c79755c920\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a7c79755c920\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#What_is_an_Artificial_Pancreas_Device_System\" >What is an Artificial Pancreas Device System?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#The_Clinical_Need_Why_Traditional_Insulin_Therapy_Falls_Short\" >The Clinical Need: Why Traditional Insulin Therapy Falls Short<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Technological_Advancements_Driving_the_Next_Generation_of_APDS\" >Technological Advancements Driving the Next Generation of APDS<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Artificial_Pancreas_Device_System_Market_Landscape\" >Artificial Pancreas Device System Market Landscape<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Segment-Level_Growth_Drivers\" >Segment-Level Growth Drivers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#The_US_and_North_America_Artificial_Pancreas_Device_System_Market\" >The US and North America Artificial Pancreas Device System Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Adoption_Challenges\" >Adoption Challenges<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Regulatory_Milestones_Key_Players_and_Product_Developments\" >Regulatory Milestones, Key Players, and Product Developments<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Key_Players_Shaping_the_Market\" >Key Players Shaping the Market<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Clinical_Outcomes_Patient_Benefits_and_Safety_Considerations\" >Clinical Outcomes, Patient Benefits, and Safety Considerations<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Beyond_Glycemic_Control_Quality_of_Life\" >Beyond Glycemic Control: Quality of Life<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Safety_Considerations\" >Safety Considerations<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\/#Future_Outlook\" >Future Outlook<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>For a century, insulin therapy has kept people with Type 1 diabetes alive, but it has never fully replicated the second-by-second responsiveness of a healthy pancreas. Artificial Pancreas Device Systems (APDS) close that gap. By pairing continuous glucose monitoring with algorithm-driven insulin pumps, these systems automate a task that once demanded constant vigilance from patients and caregivers alike. What began as a narrow clinical niche has, over the past five years, evolved into one of the fastest-growing categories in connected medical devices, reshaping not only patient outcomes but also the competitive and <a href=\"https:\/\/www.delveinsight.com\/blog\/new-era-of-diabetes-care-devices\">commercial landscape of diabetes care<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-an-artificial-pancreas-device-system\"><span class=\"ez-toc-section\" id=\"What_is_an_Artificial_Pancreas_Device_System\"><\/span><strong>What is an Artificial Pancreas Device System?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>An artificial pancreas device system is an integrated, automated technology platform that monitors blood glucose in real time and adjusts insulin delivery accordingly, with minimal manual input from the user. Rather than a single device, APDS refers to the coordinated operation of three core components working in a continuous feedback loop.<\/p>\n\n\n\n<p><strong>The Three Core Components<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous Glucose Monitor (CGM):<\/strong> A subcutaneous sensor that measures interstitial glucose every one to five minutes and transmits the reading wirelessly to the controller.<\/li>\n\n\n\n<li><strong>Insulin Pump:<\/strong> A wearable device that delivers rapid-acting insulin through a cannula or tubeless pod, capable of adjusting basal rates and issuing micro-correction boluses in real time.<\/li>\n\n\n\n<li><strong>Control Algorithm: <\/strong>The software \u201cbrain\u201d of the system, often running on the pump, a companion smartphone app, or a dedicated controller, that interprets glucose trends, predicts near-term glucose movement, and calculates the appropriate insulin dose.<\/li>\n<\/ul>\n\n\n\n<p>Together, these components form a closed loop: the CGM senses glucose, the algorithm decides, and the pump acts, after which the patient&#8217;s physiological response feeds back into the next CGM reading. Most systems on the market today are described as \u201chybrid\u201d closed-loop, meaning the algorithm automates basal insulin and correction dosing continuously, but the user still announces meals or delivers manual boluses for carbohydrate intake. A smaller number of newer systems, most notably <strong>Beta Bionics&#8217; iLet<\/strong>, operate closer to a fully closed-loop model, requiring only body weight at setup and simplified meal-size announcements rather than precise carbohydrate counts.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"382\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes-1024x382.webp\" alt=\"Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes\" class=\"wp-image-35967\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes-1024x382.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes-300x112.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes-150x56.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes-768x286.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes-1536x573.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Hybrid-Closed-Loop-Therapy-vs-Sensor-Augmented-Pump-Therapy-in-Suboptimally-Controlled-Type-1-Diabetes.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-clinical-need-why-traditional-insulin-therapy-falls-short\"><span class=\"ez-toc-section\" id=\"The_Clinical_Need_Why_Traditional_Insulin_Therapy_Falls_Short\"><\/span><strong>The Clinical Need: Why Traditional Insulin Therapy Falls Short<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Type 1 diabetes is an autoimmune condition in which the pancreas produces little or no insulin, making patients fully dependent on exogenous insulin for survival. Advanced, insulin-requiring Type 2 diabetes presents a related but distinct challenge, often layered with insulin resistance, greater variability in daily routines, and a higher average patient age. In both populations, traditional therapy, multiple daily injections (MDI) or manual, <a href=\"https:\/\/www.delveinsight.com\/report-store\/insulin-infusion-pumps-market\">non-automated insulin pumps<\/a> combined with periodic fingerstick or CGM checks, asks patients to act as their own control algorithm.<\/p>\n\n\n\n<p><strong>Where Manual Management Breaks Down<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reactive, not predictive: <\/strong>MDI and manual pumps respond to glucose excursions only after they occur, rather than anticipating them.<\/li>\n\n\n\n<li><strong>Hypoglycemia risk:<\/strong> Overcorrection of high glucose or delayed response to falling glucose remains a leading cause of severe hypoglycemic events, particularly overnight.<\/li>\n\n\n\n<li><strong>Cognitive and emotional burden: <\/strong>Patients on manual regimens must calculate carbohydrate ratios, correction factors, and insulin-on-board dozens of times per day, a burden widely documented as a driver of diabetes distress and burnout.<\/li>\n\n\n\n<li><strong>Variability across life stages:<\/strong> Growth spurts, exercise, illness, menstrual cycles, and stress all shift insulin sensitivity in ways that are difficult to track manually and easy for an adaptive algorithm to learn.<\/li>\n<\/ul>\n\n\n\n<p>This gap between the physiological demands of glycemic control and the practical limits of human attention is precisely what APDS was engineered to close. Clinical guidance has shifted accordingly: the American Diabetes Association&#8217;s 2026 Standards of Care designate automated insulin delivery as the preferred method of insulin administration for all individuals with Type 1 diabetes and for adults with Type 2 diabetes, the first time automated delivery has received the organization&#8217;s strongest recommendation for a Type 2 population, reflecting the growing recognition of insulin-dependent Type 2 diabetes as a legitimate and expanding indication for these systems.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-technological-advancements-driving-the-next-generation-of-apds\"><span class=\"ez-toc-section\" id=\"Technological_Advancements_Driving_the_Next_Generation_of_APDS\"><\/span><strong>Technological Advancements Driving the Next Generation of APDS<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Hybrid Closed-Loop Systems Mature<\/strong><\/p>\n\n\n\n<p>Hybrid closed-loop systems remain the clinical and commercial backbone of the category. Platforms such as <strong>Medtronic&#8217;s MiniMed 780G, Tandem&#8217;s t:slim X2 with Control-IQ+<\/strong>, <strong>Insulet&#8217;s Omnipod 5, and Beta Bionics&#8217; iLet Bionic Pancreas<\/strong> have each layered in meal-detection technology that identifies unannounced carbohydrate intake through glucose-trend analysis, automatically issuing corrective doses even when a patient forgets to bolus. Real-world data from a European cohort of nearly 15,000 users found that patients spent over 81% of their time in automated \u201cauto mode,\u201d achieving roughly 72% time-in-range, a level of consistency rarely achieved through manual dosing alone.<\/p>\n\n\n\n<p><strong>AI and Machine Learning Move to the Core of the Algorithm<\/strong><\/p>\n\n\n\n<p>The control algorithm is the fastest-evolving layer of the technology stack. Newer systems increasingly use machine learning to personalize insulin sensitivity factors over time, recognize individual meal and exercise patterns, and refine glucose predictions minutes to an hour ahead, rather than relying on static, population-derived formulas. This shift from rules-based to adaptive learning algorithms is also the single fastest-growing component of the APDS value chain, with control algorithm and software revenue expanding markedly faster than hardware.<\/p>\n\n\n\n<p><strong>Interoperability and Digital Health Integration<\/strong><\/p>\n\n\n\n<p>Regulatory pathways for interoperable components, such as the FDA&#8217;s designation of \u201cACE pumps\u201d and \u201ciCGMs\u201d, have opened the door to mix-and-match systems in which a patient&#8217;s preferred CGM, pump, and algorithm can be combined rather than locked into a single manufacturer&#8217;s ecosystem. Diabeloop&#8217;s DBLG2, for example, received clearance as an interoperable automated glycemic controller compatible with multiple pump and sensor brands. At the same time, companion smartphone apps, cloud-based data platforms, and remote monitoring dashboards now let clinicians and caregivers review glucose and dosing trends between visits, embedding APDS within a broader digital health and telehealth ecosystem rather than treating it as a standalone device.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"406\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management-1024x406.webp\" alt=\"Emerging-Technologies-Accelerating-Progress-in-APDS-Management\" class=\"wp-image-35968\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management-1024x406.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management-300x119.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management-150x59.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management-768x304.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management-1536x609.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Emerging-Technologies-Accelerating-Progress-in-APDS-Management.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Toward Fully Closed-Loop Operation<\/strong><\/p>\n\n\n\n<p>The next technological frontier is eliminating meal announcements altogether. Beta Bionics&#8217; iLet already requires no carbohydrate counting, only qualitative meal-size input, while investigational systems such as open-source, smartphone-based algorithms have demonstrated meaningful time-in-range even without any meal announcement. Dual-hormone approaches that pair insulin with glucagon to counteract lows are also in development, though none has yet reached FDA clearance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-artificial-pancreas-device-system-market-landscape\"><span class=\"ez-toc-section\" id=\"Artificial_Pancreas_Device_System_Market_Landscape\"><\/span><strong>Artificial Pancreas Device System Market Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/artificial-pancreas-device-system-market\">global artificial pancreas device market<\/a> was valued at <strong>USD 334 million<\/strong> in 2025 and is projected to grow at a <strong>CAGR of 16.33%<\/strong>, reaching <strong>USD 1.1 billion<\/strong> by 2034. Market growth is primarily driven by the increasing global prevalence of diabetes, which continues to expand the demand for advanced and effective diabetes management solutions. Furthermore, rising awareness of diabetes, coupled with the widespread adoption of screening initiatives, has facilitated earlier diagnosis and improved disease management, thereby accelerating the adoption of innovative technologies such as artificial pancreas systems.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-segment-level-growth-drivers\"><span class=\"ez-toc-section\" id=\"Segment-Level_Growth_Drivers\"><\/span><strong>Segment-Level Growth Drivers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Among device types, the threshold-suspended device system accounted for a significant share of the artificial pancreas device market in 2025. These systems are gaining strong market traction due to their ability to enhance patient safety and simplify diabetes management by automatically suspending insulin delivery when glucose levels fall below a predefined threshold, reducing the risk of hypoglycemia while improving overall treatment convenience.<\/p>\n\n\n\n<p>Within the artificial pancreas device systems market, growth is not evenly distributed. Insulin pumps still account for the largest share of component-level revenue, roughly half of the market in 2025, but control algorithm and software revenue is growing at <strong>more than 25%<\/strong> annually as manufacturers monetize algorithm upgrades, subscription-style app features, and AI-driven personalization layers. Homecare settings dominate end-user demand, reflecting the shift of <a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-disease-management-apps\">chronic disease management<\/a> out of clinics and into daily life, while the pediatric patient segment, historically underserved due to dosing-precision concerns in small children, is now one of the fastest-growing age cohorts as systems are cleared for progressively younger users.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-us-and-north-america-artificial-pancreas-device-system-market\"><span class=\"ez-toc-section\" id=\"The_US_and_North_America_Artificial_Pancreas_Device_System_Market\"><\/span><strong>The US and North America Artificial Pancreas Device System Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>North America remains the epicenter of commercial activity. The region accounted for <strong>approximately 43%<\/strong> of global artificial pancreas device system market revenue in 2025, and the US artificial pancreas device system market alone represents the large majority of that regional total, underpinned by concentrated device-manufacturer headquarters, relatively favorable reimbursement from commercial payers and Medicare\/Medicaid, and dense endocrinology infrastructure. Asia-Pacific, meanwhile, is recognized across multiple sources as the fastest-growing region worldwide, as diabetes prevalence rises and reimbursement frameworks mature in China, Japan, India, and South Korea.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-adoption-challenges\"><span class=\"ez-toc-section\" id=\"Adoption_Challenges\"><\/span><strong>Adoption Challenges<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Despite the significant clinical benefits offered by automated insulin delivery systems (AID systems), several barriers continue to limit broader adoption. High treatment costs remain a major challenge, with annual expenses for devices and consumables, including continuous glucose monitoring (CGM) sensors and infusion sets, typically ranging from approximately <strong>USD 4,000 to USD 12,000<\/strong>, depending on geography and reimbursement policies. In regions where insurance coverage is limited or absent, these costs can substantially restrict patient access.<\/p>\n\n\n\n<p>Adoption is particularly constrained in emerging markets across Latin America, Africa, and parts of Asia, where inadequate reimbursement, limited endocrinology infrastructure, and supply chain challenges hinder widespread availability despite the growing burden of diabetes. Additionally, the complexity of using these systems presents another obstacle. Patients must learn to operate insulin pumps, interpret sensor data and algorithm-generated alerts, and manage device settings, creating a steeper learning curve for older adults and first-time users.<\/p>\n\n\n\n<p>Administrative hurdles further delay access, as prior authorization requirements and extensive documentation in many healthcare systems can postpone the initiation of automated insulin therapy by several months. At the same time, the increasing connectivity of AID systems with smartphones, cloud-based platforms, and remote monitoring applications has elevated concerns regarding data privacy and cybersecurity, making secure wireless communication and device software protection key regulatory and engineering priorities.<\/p>\n\n\n\n<p>Nevertheless, the outlook for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/insulin-delivery-devices-market\">automated insulin delivery market<\/a> remains positive. Expanding reimbursement coverage, growing real-world evidence supporting clinical effectiveness, continuous technological advancements, and increasingly user-friendly system designs are gradually reducing historical adoption barriers. As these improvements continue, automated insulin delivery systems are expected to become more accessible to a broader patient population beyond early adopters and well-resourced healthcare settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones-key-players-and-product-developments\"><span class=\"ez-toc-section\" id=\"Regulatory_Milestones_Key_Players_and_Product_Developments\"><\/span><strong>Regulatory Milestones, Key Players, and Product Developments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Regulatory clearance pathways for APDS have matured substantially since <strong>Medtronic&#8217;s MiniMed 670G<\/strong> became the first FDA-approved hybrid closed-loop system in 2016. The FDA&#8217;s subsequent creation of interoperable device categories, ACE pumps, iCGMs, and interoperable automated glycemic controllers, allowed algorithm developers such as <strong>Tandem&#8217;s Control-IQ<\/strong> to be cleared as standalone \u201ccontrollers\u201d compatible with multiple hardware partners, rather than requiring a single vertically integrated system.<\/p>\n\n\n\n<div dir=\"ltr\" align=\"left\">\n<table style=\"border-collapse: collapse; border: 1px solid #000000;\" border=\"1\"><colgroup><col width=\"110\"><col width=\"171\"><col width=\"343\"><\/colgroup>\n<tbody>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Year<\/strong><\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Company<\/strong><\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Milestone<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">2024<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Insulet<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">FDA expanded Omnipod 5 indication to include adults with Type 2 diabetes.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">2024<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">CamAPS FX<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Received FDA approval for use in patients age 2 and older, including pregnant women.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Mar 2025<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Tandem Diabetes Care<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Launched Control-IQ+, an updated automated correction-dosing algorithm.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Aug 2025<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Tandem Diabetes Care<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Received FDA clearance for a 7-day SteadiSet infusion set, commercial launch expected 2026.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Nov 2025<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Dexcom<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">15-day G7 sensor confirmed at launch to be compatible with the iLet Bionic Pancreas and Omnipod 5, with Tandem compatibility in progress.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Early 2026<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Tandem Diabetes Care<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">FDA clearance for an Android version of the Mobi companion app, expanding smartphone-control access beyond iPhone-only users.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">2026<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Medtronic<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Advancing FDA submission for &ldquo;Instinct,&rdquo; a new Abbott-developed CGM sensor for use with the MiniMed 780G and InPen.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Feb 2026<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Insulet<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Launched the Omnipod 5 Automated Insulin Delivery System in the Middle East.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Players_Shaping_the_Market\"><\/span><strong>Key Players Shaping the Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The automated insulin delivery market is led by several key players driving innovation across insulin pumps, continuous glucose monitoring (CGM), and hybrid closed-loop technologies. <strong>Medtronic plc<\/strong> has long been the market leader with its MiniMed 780G platform, supported by the largest global endocrinologist prescriber network and an expanding portfolio of CGM sensor partnerships. <strong>Tandem Diabetes Care<\/strong> continues to strengthen its position through the t:slim X2 and compact Mobi insulin pumps powered by Control-IQ+ technology, with a strategic focus on smartphone-based control and device interoperability. <strong>Insulet Corporation<\/strong> has differentiated itself with the tubeless Omnipod 5, the only fully tubeless automated insulin delivery system commercially available in the United States and the first hybrid closed-loop system approved for adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">Type 2 diabetes<\/a>.&nbsp;<\/p>\n\n\n\n<p><strong>Beta Bionics<\/strong> has introduced the iLet Bionic Pancreas, the first FDA-cleared AID system designed to eliminate the need for carbohydrate counting or basal-rate programming, simplifying diabetes management. Meanwhile, <strong>Dexcom<\/strong> and <strong>Abbott<\/strong> play a pivotal role as leading CGM providers, with their Dexcom G6\/G7 and Abbott FreeStyle Libre and Instinct sensors serving as the foundation for most hybrid closed-loop systems, making sensor accuracy, reliability, and wear duration essential determinants of overall system performance. In Europe, <strong>Diabeloop<\/strong> is advancing the trend toward interoperable diabetes care through its DBLG2 controller, which is compatible with multiple ACE insulin pumps and integrated CGM (iCGM) sensors, reflecting the industry&#8217;s growing shift toward flexible, mix-and-match ecosystem designs.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Clinical_Outcomes_Patient_Benefits_and_Safety_Considerations\"><\/span><strong>Clinical Outcomes, Patient Benefits, and Safety Considerations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The clinical case for APDS is now supported by more than a decade of randomized controlled trials and real-world evidence. A pivotal multicentre randomized trial in patients with suboptimally controlled Type 1 diabetes found that 12 weeks of hybrid closed-loop therapy raised time-in-range from a <strong>54% <\/strong>baseline to <strong>65%<\/strong>, compared with a smaller improvement in a sensor-augmented pump control group, alongside a significantly greater reduction in HbA1c and less time spent in both hyperglycemia and hypoglycemia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Beyond_Glycemic_Control_Quality_of_Life\"><\/span><strong>Beyond Glycemic Control: Quality of Life<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Improved time-in-range and HbA1c are the headline metrics, but the patient-reported benefits are equally significant to real-world adoption. Multiple studies, including NHS real-world pilot data in children and young people, report reduced diabetes-related distress, less fear of hypoglycemia (particularly overnight), and greater confidence in independent activities such as exercise, travel, and sleeping through the night without manual glucose checks. Analyses of the International Diabetes Closed-Loop Trial further found that time-in-range improved across every baseline HbA1c subgroup, including patients already at target and those with the highest starting HbA1c, leading researchers to argue against restricting access to only the most \u201cideal\u201d candidates.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Safety_Considerations\"><\/span><strong>Safety Considerations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Automated insulin delivery systems have demonstrated a strong safety profile, with multiple built-in features designed to minimize treatment-related risks. Predictive low-glucose suspend technology, including earlier threshold suspend systems, has been associated with a 50\u201370% reduction in nocturnal hypoglycemic episodes across clinical trials and real-world studies. Since insulin dosing decisions rely heavily on continuous glucose monitoring data, sensor accuracy remains critical. Although sensor drift or compression-induced false low readings may occasionally lead to inappropriate insulin delivery, manufacturers continue to improve sensor performance, with mean absolute relative difference (MARD) serving as the standard benchmark for accuracy.<\/p>\n\n\n\n<p>Like any connected medical device, AID systems remain susceptible to occasional infusion set occlusions, tubing failures, software glitches, or product recalls, highlighting the importance of patient education and maintaining a backup manual insulin dosing plan. In addition, the wireless connectivity between the CGM, insulin pump, and smartphone applications has made cybersecurity an integral component of regulatory evaluation, with manufacturers required to demonstrate protection against unauthorized access, interference, and other cybersecurity threats.<\/p>\n\n\n\n<p>Overall, the available clinical evidence consistently indicates that, for the vast majority of eligible patients, the improvements in glycemic control, reduction in hypoglycemia, and enhanced quality of life provided by automated insulin delivery systems substantially outweigh their incremental risks compared with conventional manual insulin therapy, provided that users receive appropriate training and retain the ability to administer insulin manually when needed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Outlook\"><\/span><strong>Future Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The automated insulin delivery landscape is rapidly evolving toward highly autonomous, intelligent, and interoperable systems that minimize patient burden while improving glycemic outcomes. Although no commercially available AID system in 2026 completely eliminates user input, recent technological advances indicate that fully automated diabetes management is becoming increasingly achievable.<\/p>\n\n\n\n<p>A major trend is the transition toward fully closed-loop insulin delivery. Commercial platforms such as Beta Bionics&#8217; iLet have already simplified therapy initiation by requiring only a patient&#8217;s body weight for setup, significantly reducing the complexity of device configuration. At the same time, investigational closed-loop algorithms, including those operating on standard smartphones, have demonstrated clinically meaningful improvements in time-in-range without requiring meal announcements. These developments suggest that the next generation of commercially approved AID systems will likely eliminate the need for mealtime carbohydrate input altogether. In parallel, continued advancements in dual-hormone (insulin-glucagon) bionic pancreas technologies are expected to further improve glucose control while reducing the risk of hypoglycemia.<\/p>\n\n\n\n<p>Interoperability is also emerging as a key competitive differentiator. The FDA&#8217;s interoperable device framework is shifting the market away from proprietary, single-manufacturer ecosystems toward flexible platforms that allow patients to combine their preferred <a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-glucose-monitoring-systems-market\">continuous glucose monitor (CGM)<\/a>, insulin pump, and dosing algorithm. This evolution is fostering broader collaboration among manufacturers, exemplified by Dexcom&#8217;s expanding compatibility with platforms from Tandem Diabetes Care, Insulet, and Beta Bionics. As hardware compatibility becomes more standardized, companies are increasingly competing through algorithm performance, ease of use, and overall patient experience rather than device exclusivity.<\/p>\n\n\n\n<p>Artificial intelligence and machine learning are expected to drive the next wave of innovation by enabling highly personalized insulin therapy. Future control algorithms will move beyond population-based dosing models to continuously adapt to an individual&#8217;s physiological characteristics, including exercise habits, circadian variations in insulin sensitivity, illness-related insulin resistance, and early indicators of infusion-site failure. This level of adaptive intelligence has the potential to further enhance glycemic control while reducing the need for manual intervention.<\/p>\n\n\n\n<p>Together with expanding regulatory approvals for people with insulin-requiring type 2 diabetes and broader reimbursement support across major healthcare markets, these technological advances are positioning automated insulin delivery systems to become the standard of care rather than a specialized treatment option. Over the coming years, AID systems are expected to evolve into fully autonomous, personalized, and interoperable platforms that simplify diabetes management while delivering improved clinical outcomes for a growing population of insulin-treated individuals.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/artificial-pancreas-device-system-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook-1024x194.webp\" alt=\"Artificial Pancreas Device Systems Market Outlook\" class=\"wp-image-35966\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Artificial-Pancreas-Device-Systems-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>For a century, insulin therapy has kept people with Type 1 diabetes alive, but it has never fully replicated the second-by-second responsiveness of a healthy pancreas. Artificial Pancreas Device Systems (APDS) close that gap. By pairing continuous glucose monitoring with algorithm-driven insulin pumps, these systems automate a task that once demanded constant vigilance from patients [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35964,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19832,23072,653,20388,812,19935,22845,18890,19928],"industry":[17226],"therapeutic_areas":[17239],"class_list":["post-35962","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-apds","tag-artificial-pancreas-device-systems","tag-chronic-disease","tag-continuous-glucose-monitoring-system","tag-diabetes","tag-diabetes-apps","tag-diabetes-care-devices","tag-diabetes-management","tag-insulin-pumps","industry-medical-devices","therapeutic_areas-gastroenterology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The Artificial Pancreas Revolution in Diabetes Management<\/title>\n<meta name=\"description\" content=\"Artificial pancreas device system is automated technology platform that monitors blood glucose in real time &amp; adjusts insulin delivery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Artificial Pancreas Revolution in Diabetes Management\" \/>\n<meta property=\"og:description\" content=\"Artificial pancreas device system is automated technology platform that monitors blood glucose in real time &amp; adjusts insulin delivery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T12:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Artificial Pancreas Revolution in Diabetes Management","description":"Artificial pancreas device system is automated technology platform that monitors blood glucose in real time & adjusts insulin delivery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management","og_locale":"en_US","og_type":"article","og_title":"The Artificial Pancreas Revolution in Diabetes Management","og_description":"Artificial pancreas device system is automated technology platform that monitors blood glucose in real time & adjusts insulin delivery.","og_url":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-08-12T12:09:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Artificial Pancreas Device Systems: Engineering a New Era in Diabetes Management","datePublished":"2026-08-12T12:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management"},"wordCount":2897,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management.webp","keywords":["APDS","Artificial Pancreas Device Systems","Chronic disease","Continuous Glucose Monitoring System","Diabetes","Diabetes Apps","Diabetes Care Devices","Diabetes Management","Insulin Pumps"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management","url":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management","name":"The Artificial Pancreas Revolution in Diabetes Management","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management.webp","datePublished":"2026-08-12T12:09:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Artificial pancreas device system is automated technology platform that monitors blood glucose in real time & adjusts insulin delivery.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/artificial-pancreas-device-systems-in-diabetes-management#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management.webp","width":466,"height":284,"caption":"artificial-pancreas-device-systems-in-diabetes-management"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/artificial-pancreas-device-systems-in-diabetes-management-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">APDS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Artificial Pancreas Device Systems<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Continuous Glucose Monitoring System<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Diabetes Apps<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Diabetes Care Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Diabetes Management<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Insulin Pumps<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">APDS<\/span>","<span class=\"advgb-post-tax-term\">Artificial Pancreas Device Systems<\/span>","<span class=\"advgb-post-tax-term\">Chronic disease<\/span>","<span class=\"advgb-post-tax-term\">Continuous Glucose Monitoring System<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Diabetes Apps<\/span>","<span class=\"advgb-post-tax-term\">Diabetes Care Devices<\/span>","<span class=\"advgb-post-tax-term\">Diabetes Management<\/span>","<span class=\"advgb-post-tax-term\">Insulin Pumps<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 hours ago","modified":"Updated 2 hours ago"},"absolute_dates":{"created":"Posted on Aug 12, 2026","modified":"Updated on Aug 12, 2026"},"absolute_dates_time":{"created":"Posted on Aug 12, 2026 5:39 pm","modified":"Updated on Aug 12, 2026 3:59 pm"},"featured_img_caption":"artificial-pancreas-device-systems-in-diabetes-management","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35962"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35962\/revisions"}],"predecessor-version":[{"id":35969,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35962\/revisions\/35969"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35964"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35962"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35962"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}